FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Monica Ligueros-Saylan

Research Profile

Chemicals & Drugs

Procedures

Disorders

Type 2 Diabetes Mellitus

Concepts & Ideas

Physiology

Drug Interactions

Co-author Network

Publications

TOP 3
Yan-Ling He; Monica Ligueros-Saylan; D Serra; Y Wang; Y Zhang; W P Dole
Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
Yan-Ling He; Jessica Valencia; Yiming Zhang; Sherwyn L Schwartz; Monica Ligueros-Saylan; James Foley; William P Dole
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
Monica Ligueros-Saylan; James Foley; Anja Schweizer; A Couturier; W Kothny
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Monica Ligueros-Saylan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Yan-Ling He; Monica Ligueros-Saylan; D Serra; Y Wang; Y Zhang; W P Dole
Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
Current medical research and opinion 2011;27(7):1453-63.
2010: Yan-Ling He; Jessica Valencia; Yiming Zhang; Sherwyn L Schwartz; Monica Ligueros-Saylan; James Foley; William P Dole
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
British journal of clinical pharmacology 2010;70(1):34-42.
2010: Monica Ligueros-Saylan; James Foley; Anja Schweizer; A Couturier; W Kothny
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.
Diabetes, obesity & metabolism 2010;12(6):495-509.
2010: Jessie Gu; Adele Noe; Priya Chandra; Suliman Al-Fayoumi; Monica Ligueros-Saylan; Ramesh Sarangapani; Suzanne Maahs; Gary Ksander; Dean F Rigel; Arco Y Jeng; Tsu-Han Lin; Weiyi Zheng; William P Dole
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Journal of clinical pharmacology 2010;50(4):401-14.
2009: Yan-Ling He; Ron Sabo; Franck Picard; Yibin Wang; Jerry Herron; Monica Ligueros-Saylan; William P Dole
Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
Current medical research and opinion 2009;25(5):1265-72.
2009: Chiara Dalla Man; Gerlies Bock; Paula D Giesler; Denise B Serra; Monica Ligueros-Saylan; James Foley; Michael Camilleri; Gianna Toffolo; Claudio Cobelli; Robert A Rizza; Adrian Vella
Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
Diabetes care 2009;32(1):14-8.
2008: D Serra; Yan-Ling He; J Bullock; G-J Riviere; S Balez; S Schwartz; Y Wang; Monica Ligueros-Saylan; V Jarugula; William P Dole
Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
International journal of clinical pharmacology and therapeutics 2008;46(7):349-64.
2008: Yan-Ling He; Brian Flannery; Joelle Campestrini; Selene Leon; Miguel A Zinny; Monica Ligueros-Saylan; Venkateswar Jarugula
Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.
Current medical research and opinion 2008;24(6):1703-9.
2008: Yan-Ling He; Ron Sabo; Joelle Campestrini; Yibin Wang; Gilles-Jacques Riviere; Jace C Nielsen; Mitchell Rosenberg; Monica Ligueros-Saylan; Dan Howard; William P Dole
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.
British journal of clinical pharmacology 2008;65(3):338-46.
2008: Koichiro Azuma; Zofia Rádiková; Juliet Mancino; Frederico G S Toledo; Ernestine Thomas; Cyrous Kangani; Chiara Dalla Man; Claudio Cobelli; Jens J Holst; Carolyn F Deacon; Yanling He; Monica Ligueros-Saylan; Denise Serra; James Foley; David E Kelley
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism 2008;93(2):459-64.
2008: Yan-Ling He; Monica Ligueros-Saylan; Gangadhar Sunkara; Ron Sabo; Charlie Zhao; Yibin Wang; Joelle Campestrini; Francoise Pommier; Kiran Dole; Alan Marion; William P Dole; Dan Howard
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
Journal of clinical pharmacology 2008;48(1):85-95.
2007: Surya P Ayalasomayajula; Kiran Dole; Yan-Ling He; Monica Ligueros-Saylan; Yibin Wang; Joelle Campestrini; Henri Humbert; Gangadhar Sunkara
Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
Current medical research and opinion 2007;23(12):2913-20.
2007: Yan-Ling He; Ron Sabo; Gangadhar Sunkara; Marie-Noelle Bizot; Gilles-Jacques Riviere; Selene Leon; Monica Ligueros-Saylan; William P Dole; Dan Howard
Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.
Journal of clinical pharmacology 2007;47(8):998-1004.
2007: Yan-Ling He; Ron Sabo; Joelle Campestrini; Yibin Wang; Monica Ligueros-Saylan; Kenneth C Lasseter; Stacy C Dilzer; Dan Howard; William P Dole
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.
European journal of clinical pharmacology 2007;63(7):677-86.
2007: Yan-Ling He; Ron Sabo; Gilles-Jacques Riviere; Gangadhar Sunkara; Selene Leon; Monica Ligueros-Saylan; Mitchell Rosenberg; William P Dole; Dan Howard
Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Current medical research and opinion 2007;23(5):1131-8.
2007: Yan-Ling He; Yibin Wang; Julie M Bullock; Carolyn F Deacon; Jens Juul Holst; Beth E Dunning; Monica Ligueros-Saylan; James Foley
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
Journal of clinical pharmacology 2007;47(5):633-41.
2007: Bogdan Balas; Muhammad R Baig; Catherine Watson; Beth E Dunning; Monica Ligueros-Saylan; Yibin Wang; Yan-Ling He; Celia Darland; Jens J Holst; Carolyn F Deacon; Kenneth Cusi; Andrea Mari; James Foley; Ralph DeFronzo
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
The Journal of clinical endocrinology and metabolism 2007;92(4):1249-55.
2007: Yan-Ling He; Brian M Sadler; Ron Sabo; Sebastien Balez; Yibin Wang; Joelle Campestrini; Aziz Laurent; Monica Ligueros-Saylan; Dan Howard
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
Clinical pharmacokinetics 2007;46(9):787-802.
2007: Yan-Ling He; Denise Serra; Yibin Wang; Joelle Campestrini; Gilles-Jacques Riviere; Carolyn F Deacon; Jens J Holst; Sherwyn Schwartz; Jace C Nielsen; Monica Ligueros-Saylan
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
Clinical pharmacokinetics 2007;46(7):577-88.
2007: Yan-Ling He; Anne Horowitz; Catherine E Watson; James Foley; William Sallas; Monica Ligueros-Saylan
Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes.
Journal of clinical pharmacology 2007;47(1):127-31.
2005: Andrea Mari; W M Sallas; Yan-Ling He; C Watson; Monica Ligueros-Saylan; Beth E Dunning; Carolyn F Deacon; Jens Juul Holst; James Foley
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism 2005;90(8):4888-94.
2004: Helene Sabia; Gangadhar Sunkara; Monica Ligueros-Saylan; Yibin Wang; Harold Smith; James McLeod; Pratapa Prasad
Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects.
European journal of clinical pharmacology 2004;60(6):407-12.
2004: Gangadhar Sunkara; Hilde Bigler; Yibin Wang; Harold Smith; Pratapa Prasad; James McLeod; Monica Ligueros-Saylan
The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Current medical research and opinion 2004;20(1):41-8.
2001: Steven E Kahn; B Montgomery; W Howell; Monica Ligueros-Saylan; C H Hsu; Damayanthi Devineni; James F McLeod; A Horowitz; James Foley
Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
The Journal of clinical endocrinology and metabolism 2001;86(12):5824-9.